相关实验视频
Updated: Jun 21, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
对卡维迪洛尔对多克索鲁比诱导心脏毒性的潜在保护的机制性见解
Elsayed A Elmorsy1, Sameh Saber2, Rabab S Hamad3
1Department of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia; Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
概括
卡维迪醇通过减少氧化应激,DNA损伤和亡来保护心脏免受化疗药物多克索鲁比 (DOX) 的影响. 这篇评论详细介绍了卡尔维迪洛尔.
科学领域:
- 心血管药理学心血管药理学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 多克索鲁比 (DOX) 是一种重要的化疗剂,但会导致剂量依赖的心脏毒性,限制其使用.
- 了解DOX诱导心脏毒性的机制对于开发心脏保护策略至关重要.
- 卡维迪醇已经显示出减轻化疗引起的心脏损伤的潜力.
研究的目的:
- 探索卡韦迪醇对多克索鲁比诱导心脏毒性的心脏保护作用的分子机制.
- 提供关于卡维迪洛如何对抗特定的DOX诱导的心脏损伤途径的全面审查.
主要方法:
- 文献综述专注于分子和细胞机制.
- 对调查多克索鲁比心脏毒性影响的研究进行分析.
- 检查详细研究的研究在分子水平上卡维迪洛的保护作用.
主要成果:
- doxorubicin 通过氧化应激,DNA 损伤,铁不平衡,破坏自,失调,亡,拓酶2-β 问题和炎症诱导心脏毒性.
- 卡维迪醇通过抗氧化活性,铁平衡,自调节,恢复平衡和抗亡作用来减轻这些影响.
- 卡维迪醇调节Bcl-2蛋白质,激活Akt信号传递,控制2β拓酶,并影响氨酸- ангиотензин-阿尔多斯特系统.
结论:
- 卡维迪洛尔在分子水平上提供了对多克索鲁比诱导的心脏毒性的多方面的保护.
- 详细了解这些机制可以指导针对性心脏保护疗法的开发.
- 这篇评论强调了卡维迪醇作为一种有前途的药物,用于管理化疗相关的心脏损伤.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
964
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
964
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
733
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
733